The Chalcogen, X, Is In A -c(=x)- Group, Which Group Is Bonded Directly To The Nitrogen Patents (Class 558/170)
-
Publication number: 20140315834Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.Type: ApplicationFiled: September 23, 2013Publication date: October 23, 2014Applicant: Medicon Pharmaceuticals, Inc.Inventor: Basil RIGAS
-
Publication number: 20140178461Abstract: Novel compounds and pharmaceutical compositions thereof administered by the respiratory route for prevention and/or treatment of lung and brain cancer and precancerous conditions thereof.Type: ApplicationFiled: September 23, 2013Publication date: June 26, 2014Inventor: Basil RIGAS
-
Publication number: 20140121185Abstract: Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.Type: ApplicationFiled: September 23, 2013Publication date: May 1, 2014Applicant: MEDICON PHARMACEUTICALS, INC.Inventor: Basil RIGAS
-
Publication number: 20140113884Abstract: Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.Type: ApplicationFiled: April 4, 2012Publication date: April 24, 2014Inventors: John David Imig, William B. Campell, John Russell Falck
-
Publication number: 20140017797Abstract: This invention concerns isotopically coded or non-isotopically coded affinity-tags for analysis of certain target molecules in complex samples, in particular for mass spectrometric analysis of proteomic samples. The affinity-tags have the following general formula X-SPACER-OPO3H2, wherein X is a functional group or moiety capable of reacting with a functional group of a protein, peptide, DNA, lipid, sugar and/or steroid. These phosphate affinity tags (‘PTAG’) are capable of high but reversible binding to metal-oxides like TiO2. Due to this property, tagged sample fractions can be isolated from non-tagged sample fraction by affinity chromatography. The binding of organophosphate to metal-oxides remains intact during multiple washings of preferably acidic solutions to remove non-specifically bound components. PTAG's are also envisaged wherein X is selected such that it is capable of binding proteins, peptides, nucleic acid molecules, lipids, carbohydrates, steroids and the like.Type: ApplicationFiled: December 13, 2011Publication date: January 16, 2014Applicant: De Staadt der Nederlanden, vert doorde minister van VWSInventor: Jamila Willhelmina Zomer-Elhadari
-
Publication number: 20130281387Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Publication number: 20130274230Abstract: The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.Type: ApplicationFiled: April 16, 2013Publication date: October 17, 2013Applicant: Allergan, Inc.Inventors: Richard L. Beard, Tien Duong, John E. Donello, Veena Viswanath, Michael E. Garst
-
Patent number: 8501715Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.Type: GrantFiled: April 13, 2011Date of Patent: August 6, 2013Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20130143056Abstract: Embodiments of the invention include linking agents including photo groups and vinyl groups and coatings and devices that incorporate such linking agents, along with related methods. Exemplary methods herein include methods of priming substrates and methods of coating substrates using compounds having the formula R1—X—R2, wherein R1 is a radical comprising a vinyl group, X is a radical comprising from about one to about twenty carbon atoms, and R2 is a radical comprising a photoreactive group. Embodiments herein also include linking agents having the formula R1—X—R2, wherein R1 is a radical comprising a vinyl group, X is a radical comprising from about one to about twenty carbon atoms, and R2 is a radical comprising a photoreactive group. Other embodiments are also included herein.Type: ApplicationFiled: June 7, 2012Publication date: June 6, 2013Applicant: SURMODICS, INC.Inventors: Dale G. Swan, Aleksey V. Kurdyumov, Bruce M. Jelle
-
Publication number: 20130022628Abstract: The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. Compounds of the present invention have immunomodulating properties like adjuvants. In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targeting thereof. Accordingly, compounds of the invention find use in human and veterinary medicine both as immunogens and diagnostic tools.Type: ApplicationFiled: May 7, 2012Publication date: January 24, 2013Applicant: OM PHARMAInventors: Jacques BAUER, Olivier MARTIN, Sylvain RODRIGUEZ, Stéphane MOUTEL
-
Patent number: 8334408Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.Type: GrantFiled: May 4, 2012Date of Patent: December 18, 2012Assignee: Ludwig Institute for Cancer ResearchInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Publication number: 20120283463Abstract: The present invention discloses processes for the preparation of 3-[(1R,2R)-3-(dimethyl-amino)-1-ethyl-2-methyl-propyl]phenol (Tapentadol), salts thereof and related compounds of formula (A), including stereoisomers and pharmaceutically acceptable salts thereof, and to certain intermediates used in such process.Type: ApplicationFiled: December 26, 2010Publication date: November 8, 2012Applicant: MAPI PHARMA LIMITEDInventors: Ehud Marom, Michael Mizhiritskii
-
Patent number: 8293219Abstract: Use of long carbon chain quaternary ammonium salt phosphoric acid ester of formula (I) as conditioner for hair.Type: GrantFiled: October 30, 2007Date of Patent: October 23, 2012Assignee: Nanjing Huashi Chemical Co., LtdInventors: Changguo Wang, Evelyn Su
-
Publication number: 20120252764Abstract: The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents.Type: ApplicationFiled: May 11, 2012Publication date: October 4, 2012Applicant: Perscitus Biosciences, LLCInventor: James P. Thomas
-
Publication number: 20120208917Abstract: The invention relates to a dental restorative material which comprises (a) at least one antimicrobially active compound of Formula (I) [AG]m-R1—Z—SP—Y—R2—[WG]p??(I), or a filler that is surface-modified with at least one compound of Formula (I), (b) at least one radically polymerizable monomer and (c) at least one initiator for the radical polymerization. The invention also relates to a use of such dental restorative material for the preparation of an adhesive, primer, cement, coating material or filling material. The invention also relates to a dental material which comprises at least one compound of Formula (I), as well as a use of a compound of Formula (I) for modifying the surface of a substrate selected from ceramic materials, noble and non-noble metals, hard tooth structure, tooth enamel, dentine, collagen, soft tissue, mucous membrane and leather.Type: ApplicationFiled: February 8, 2012Publication date: August 16, 2012Applicant: IVOCLAR VIVADENT AGInventors: Ulrich SALZ, Thorsten BOCK, Christoph Peter FIK, Jörg TILLER, Volker RHEINBERGER
-
Patent number: 8188313Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.Type: GrantFiled: September 13, 2011Date of Patent: May 29, 2012Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer ResearchInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Patent number: 8039670Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or oType: GrantFiled: October 25, 2006Date of Patent: October 18, 2011Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of BirminghamInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Publication number: 20110130349Abstract: The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventors: Jesse Chow, Fabian Gusovksy, Lynn Hawkins, Mark Spyvee
-
Publication number: 20110124606Abstract: Disclosed are: a sense-improving agent which comprises, as an active ingredient, a phospholipid or a sphingosine-containing phospholipid and/or a derivative thereof, particularly a sphingomyelin, and which has an effect of improving the dulling of senses at a periphery when ingested orally or directly applied to the skin; and a sense-improving food, beverage, feed or cosmetic comprising the sense-improving agent. The phospholipid to be used may be a chemically synthesized phospholipid or a naturally occurring phospholipid, preferably a phospholipid derived from an edible material such as soybean and egg yolk, particularly preferably a phospholipid derived from milk.Type: ApplicationFiled: November 19, 2008Publication date: May 26, 2011Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Tatsuya Watanabe, Yuko Haruta, Ken Kato, Toshimitsu Yoshioka
-
Patent number: 7902176Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.Type: GrantFiled: May 27, 2004Date of Patent: March 8, 2011Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Patent number: 7893291Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: February 17, 2009Date of Patent: February 22, 2011Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20110040053Abstract: A polysiloxane includes a structural unit in which a functional group represented by a general formula of (in the formula, each of R1, R2, and R3 is independently an alkyl group with a carbon number of 1 or more and 6 or less and m is an integer of 2 or more and 6 or less), an ester bond or an amide bond, a spacer, and a silicon atom are bonded sequentially.Type: ApplicationFiled: March 31, 2009Publication date: February 17, 2011Applicant: SHISEIDO COMPANY, LTD.Inventors: Yukimitsu Suda, Kazuyuki Miyazawa
-
Publication number: 20100254931Abstract: Use of long carbon chain quaternary ammonium salt phosphoric acid ester of formula (I) as conditioner for hair.Type: ApplicationFiled: October 30, 2007Publication date: October 7, 2010Applicant: NANJING ZHONGSHI CHEMICAL CO., LTD.Inventors: Changguo Wang, Evelyn Su
-
Patent number: 7772402Abstract: The invention relates to compounds having general formula I in which X represents an optically detectable moiety, n is an integer with 1?n?20, R1 is an unbranched or branched alkyl group having 1 to 20 carbon atoms, and R2 is hydrogen or —CH2—O—R3 group, wherein R3 has the same meaning as R1. These compounds are useful as inhibitors of lipolytic enzymes and can be used as tools for analysis as well as discrimination of lipolytic enzymes in biological samples.Type: GrantFiled: June 23, 2009Date of Patent: August 10, 2010Assignee: Austria Wirtschaftsservice Gesellschaft Mit Beschrankter HaftungInventors: Albin Hermetter, Olga Oskolkova
-
Patent number: 7678426Abstract: Perfluoropolyether amide-linked phosphonates and derivatives thereof are provided. Compositions containing perfluoropolyether amide-linked phosphonates or derivatives thereof, perfluoropolyether amide-linked phosphates or derivatives thereof, or combinations thereof are also provided. Additionally, articles, methods of making articles, and methods of reducing contaminant adhesion to a substrate are described.Type: GrantFiled: July 7, 2004Date of Patent: March 16, 2010Assignee: 3M Innovative Properties CompanyInventors: Richard M. Flynn, Mark J. Pellerite
-
Publication number: 20100041790Abstract: Polymerizable dental material, characterized in that it contains at least one (meth)acrylamide phosphate of the following general formula (I): in which R1 is H or CH3; R2 is H or a C1-C4 alkyl radical or forms together with the nitrogen atom to which it is bonded and one or more atoms which belong to R3 or R3? a heterocyclic ring; R3, R3? independently of each other are a linear or branched aliphatic C1-C50 radical with a valency of m+n or p+n, an aromatic C6-C18 radical with a valency of m+n or p+n, or a cycloaliphatic, araliphatic or heterocyclic C3-C18 radical with a valency of m+n or p+n, wherein the carbon chains of the radical or radicals can be interrupted by O, S, CONR4, OCONH, or form together with one or more atoms which belong to R2 and the nitrogen atom, to which the R2 is bonded a heterocyclic ring, R3? being H if p=0, and R4 being H, C1-C10 alkyl, C6-C12 aryl, C6-C10 aralkyl or a bicyclic C4-C12 radical; n is 1, 2, 3 or 4 if p=0, and is 1 or 2 if p?0; m is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4;Type: ApplicationFiled: October 23, 2009Publication date: February 18, 2010Applicant: IVOCLAR VIVADENT AGInventors: Norbert MOSZNER, Iris LAMPARTH, Frank ZEUNER, Ulrich SALZ, Angela MUCKE, Jorg ZIMMERMANN, Jorg ANGERMANN, Volker M. RHEINBERGER
-
Patent number: 7625882Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.Type: GrantFiled: September 28, 2006Date of Patent: December 1, 2009Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel
-
Patent number: 7601845Abstract: The invention relates to compounds having general formula I in which X represents an optically detectable moiety, n is an integer with 1?n?20, R1 is an unbranched or branched alkyl group having 1 to 20 carbon atoms, and R2 is hydrogen or —CH2—O—R3 group, wherein R3 has the same meaning as R1. These compounds are useful as inhibitors of lipolytic enzymes and can be used as tools for analysis as well as discrimination of lipolytic enzymes in biological samples.Type: GrantFiled: September 16, 2005Date of Patent: October 13, 2009Assignee: Austria Wirtschaftsservice Gesellschaft mit beschrankter HaftungInventors: Albin Hermetter, Olga Oskolkova
-
Patent number: 7560584Abstract: The present invention is directed to novel compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases, to novel adjuvant formulations which include at least one of the adjuvant compounds of the invention, to novel immunostimulatory compositions which comprise an antigen and at least one of the adjuvant compounds of the invention, and to methods for the immunization of an animal by co-administration of a compound of the invention with an antigen against which the animal is to be immunized.Type: GrantFiled: December 28, 2004Date of Patent: July 14, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Lynn D. Hawkins, Sally T. Ishizaka, Michael Lewis, Pamela McGuinness, Jeffrey Rose
-
Patent number: 7514556Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: July 30, 2007Date of Patent: April 7, 2009Assignee: Methylgene Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 7504388Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: July 19, 2005Date of Patent: March 17, 2009Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20080318901Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.Type: ApplicationFiled: May 6, 2005Publication date: December 25, 2008Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Kevin R. Lynch, Timothy L. Macdonald, Brian H. Heasley
-
Publication number: 20080287687Abstract: The present invention relates to a production method of a compound represented by the formula (3), which includes reacting a compound represented by the formula (2) with a diphenylmethyl halide compound represented by the formula (1) in the presence of alkali metal alkoxide. According to the method of the present invention, compound (3) can be produced at a high purity and in a high yield. wherein each symbol is as defined in the specification, *1 and *2 each show an asymmetric carbon atom, and the configuration of the asymmetric carbon atom of *1 and *2 is (S,S) or (R,R).Type: ApplicationFiled: October 31, 2007Publication date: November 20, 2008Applicant: AJINOMOTO CO. INCInventors: Takayuki Hamada, Kunisuke Izawa, Vadim A. Soloshonok
-
Patent number: 7429575Abstract: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.Type: GrantFiled: January 9, 2007Date of Patent: September 30, 2008Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20080234405Abstract: A material contains at least a polymerizable N,O-functionalized acrylic acid hydroxyamide of the Formula (I) in which A is an n+m-valent linear or branched aliphatic C1 to C50 radical, in which the carbon chain can be interrupted by O, S, —CO—O—, CO—NH, O—CO—NH or NH—CO—NH, an n+m-valent aromatic C6 to C18 radical or an n+m-valent cycloaliphatic or heterocyclic C3 to C18 radical, wherein the radicals can carry one or more substituents, Y is not present, or is O, S, an ester, amide or urethane group, R1 is hydrogen, an aliphatic C1 to C20 alkyl or C3 to C8 cycloalkyl radical which can carry one or more substituents, R2 is H or a C1 to C10 alkyl radical, R3 is not present or is a C1 to C16 alkylene radical which can be interrupted by O, HG is not present, is —COOH, —P?O(OH)2; —P?O(OH)(OR4); —O—P?O(OH)2, —SO2OH or —O—P?O(OH)(OR4), R4 is a C1 to C15 alkyl radical, phenyl or benzyl radical and n is a number from 1 to 5 and m a number from 0 to 3.Type: ApplicationFiled: September 11, 2007Publication date: September 25, 2008Applicant: Ivoclar Vivadent AGInventors: Norbert Moszner, Iris Lamparth, Urs Karl Fischer, Frank Zeuner, Armin de Meijere, Volker M. Rheinberger
-
Publication number: 20080207490Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.Type: ApplicationFiled: July 7, 2006Publication date: August 28, 2008Applicants: POSTECH Foundation, POSCOInventors: Kyung-Moo Yea, Jae-Yoon Kim, Jong-Hyun Kim, Byoung-Dae Lee, Seung-Je Lee, Tae-Hoon Lee, Pann-Ghill Suh, Sung-Ho Ryu
-
Patent number: 7408075Abstract: Aspects of the present invention include methods of synthesizing phosphocholine analogues and the phosphocholine conjugates formed therefrom and their use in preventing infections caused by microorganisms.Type: GrantFiled: March 21, 2006Date of Patent: August 5, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Louis J Rezanka
-
Patent number: 7378538Abstract: A compound of the invention is a specific compound having a phosphorylcholine group, and a polymer of the invention comprises at least 1 mol % of repeating units with a phosphorylcholine group and has a number-average molecular weight of 1,000 or more, the repeating units with a phosphorylcholine group being represented by the formula (II): wherein A is a bond selected from a single bond, —O—, —COO—, —OOC—, —CONH—, —NH—, —NHCO—, —NR2— and —CH2O— where R2 is an alkyl group having 1 to 6 carbon atoms; and m is an integer of 1 to 12.Type: GrantFiled: February 18, 2004Date of Patent: May 27, 2008Assignee: Tokai UniversityInventors: Yu Nagase, Masataka Oku, Kazuhiko Ishihara, Yasuhiko Iwasaki
-
Patent number: 7186704Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: November 24, 2003Date of Patent: March 6, 2007Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin
-
Patent number: 7153842Abstract: The present invention discloses phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal.Type: GrantFiled: December 20, 2004Date of Patent: December 26, 2006Assignee: Schering-Plough Animal Health CorporationInventors: Scott Hecker, Sunil V. Pansare, Tomasz W Glinka
-
Patent number: 7141557Abstract: A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.Type: GrantFiled: September 20, 2004Date of Patent: November 28, 2006Assignees: Wake Forest University, University of North Carolina at Chapel HillInventors: Louis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq
-
Patent number: 7135584Abstract: A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.Type: GrantFiled: July 13, 2004Date of Patent: November 14, 2006Assignees: Wake Forest University, University of North Carolina at Chapel HillInventors: Louis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq
-
Patent number: 7101864Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thixophosphpnate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.Type: GrantFiled: September 19, 2000Date of Patent: September 5, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Claudio Salomon
-
Patent number: 7034176Abstract: Intermediates used in the preparation of compounds of formula I, or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.Type: GrantFiled: December 16, 2004Date of Patent: April 25, 2006Assignee: Astrazeneca ABInventors: Thomas Elebring, Peter Guzzo, Anders Holmén, Thomas Olsson, Marianne Swanson, Sverker Von Unge
-
Patent number: 6911553Abstract: The invention is directed to compounds of formula (I) wherein R1 alkyl, alkenyl or alkynyl having from 6 to 24 carbon atoms; n=0-12; X=oxygen or NH; and the physiologically safe salts, esters, optically active forms, racemates and derivatives thereof which can be metabolized in vivo to yield compounds of general formula (I), methods of preparing same, and drugs containing said compounds, for treating bone metabolic disorders.Type: GrantFiled: September 29, 2000Date of Patent: June 28, 2005Assignee: Roche Diagnostics GmbHInventors: Angelika Esswein, Lothar Kling
-
Patent number: 6875757Abstract: The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.Type: GrantFiled: March 19, 2001Date of Patent: April 5, 2005Assignee: University of Tennessee Research FoundationInventors: Duane D. Miller, Gabor Tigyi, James T. Dalton, Vineet M. Sardar, Don B. Elrod, Huiping Xu, Daniel L. Baker, Dean Wang, Karoly Liliom, David J. Fischer, Tamas Virag, Nora Nusser
-
Patent number: 6846925Abstract: The invention related to colchinol derivatives of the formula (I): Wherein: R1; R2 and R3 are each independently hydroxy, phosphoryloxy (—OP3H2), C1-4alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R1, R2 and R3 are C1-4alkoxy; A is —CO—, —C(O)O—, —CON(R8)— (wherein R8 is hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl or hydroxyC1-3alkly); a is an integer from 1 to 4 inclusive; Ra and Rb are independently selected from hydrogen, hydroxy and amino; B is —O—, —CO—, N(R9)CO—, —CON(R9)—, —N(R9)C(O)O—, —N(R9)CON(R10)—, —N(R9)SO2—, —SO2N(R9)— or a direct single blond (wherein R9 and R10 are independently selected from hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl and hydroxyC1-3alkyl); b is O or an integer from 1 to 4 inclusive, (provided that when b is O, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, N-(C1-4alkyl)amino, N,N-di(C1-3alkyl)amino, or of the formula —Y1(CH2)0R11 or —NHCH(R12)COOH; [whType: GrantFiled: November 12, 2003Date of Patent: January 25, 2005Assignee: Angiogene Pharmaceuticals LimitedInventor: Jean Claude Arnould
-
Patent number: 6838452Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: May 27, 2003Date of Patent: January 4, 2005Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin
-
Publication number: 20040192770Abstract: The present invention relates to the preparation and biological activity of 3-deoxy-Dmyo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor 5 agents which effectively inhibit the growth of mammalian cells.Type: ApplicationFiled: December 11, 2003Publication date: September 30, 2004Inventors: Alan P. Kozikowski, Lixin Qiao, Garth Powis
-
Publication number: 20040142909Abstract: The invention related to colchinol derivatives of the formula (I): Wherein; R1; R2 and R3 are each independently hydroxy, phosphoryloxy (—OPO3H2), C1-4alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R1, R2 and R3 are C1-4alkoxy; A is —CO—, —C(O)O—, —CON(R8)— (wherein R8 is hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl or hydroxyC1-3alkyl); a is an integer from 1 to 4 inclusive; Ra and Rb are independently selected from hydrogen, hydroxy and amino; B is —O—, —CO—, N(R9)CO—, —CON(R9)—, —N(R9)C(O)O—, —N(R9)CON(R10)—, —N(R9)SO2—, —SO2N(R9)— or a direct single blond (wherein R9 and R10 are independently selected from hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl and hydroxyC1-3alkyl); b is O or an integer from 1 to 4 inclusive, (provided that when bis O, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolType: ApplicationFiled: November 12, 2003Publication date: July 22, 2004Applicant: ANGIOGENE PHARMACEUTICALS LIMITEDInventor: Jean Claude Arnould